E-47 | More than Meets the Eye: Association of Mild Tricuspid Regurgitation with Adverse Outcomes following Transcatheter Aortic Valve Replacement

While it is known that patients with moderate or severe tricuspid regurgitation (TR) are at a higher risk of adverse events following transcatheter aortic valve replacement (TAVR), the impact of mild TR is less well understood. We aimed to further investigate the relationship between mild TR and adverse outcomes among patients undergoing TAVR at our center. A retrospective study was conducted at a major academic center on patients undergoing TAVR from 2018-2022. Patients were placed into 2 groups: those without/trivial TR (WTR) and those with mild TR (MTR). We excluded those with moderate/severe TR. The analysis examined in-hospital deaths and all-cause mortality at 30 days, as well as 6 and 12 months after TAVR. We also examined major bleeding events, major adverse cardiovascular events (MACE), and congestive heart failure (CHF) exacerbation at 6 and 12 months. T and Chi-square tests were used to analyze continuous and categorical variables, respectively. A total of 221 patients were identified in the analysis. The mean age was 76 years old (73.8% were male). Those with MTR were more likely to have A-fib (p=0.0001) and coronary artery disease (p=0.013). Furthermore, MTR patients had significantly higher rates of MACE at 6 months, major bleeding events at 6 and 12 months, CHF exacerbation at 6 and 12 months, all-cause mortality at 30 days and 6 months, and in-hospital deaths. There were no significant differences in death and MACE at 12 months (Fig. 1). Patients with even mild TR experienced worse outcomes following TAVR. The nature of this association is less clear from our study.